Clinical Trials Logo

Clinical Trial Summary

This study is designed to assess safety, tolerability and pharmacokinetic data for multiple doses of PF-06669571 in subjects with idiopathic Parkinson's disease. In addition, this study will assess whether PF-06669571 is able to demonstrate superior efficacy compared with placebo in the treatment of the motor symptoms of idiopathic Parkinson's disease.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02565628
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 1
Start date November 16, 2015
Completion date May 13, 2016

See also
  Status Clinical Trial Phase
Completed NCT03665493 - Dopamine Effect on Inhibitory Control N/A
Completed NCT02227355 - Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease N/A
Completed NCT01026428 - A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics Phase 1/Phase 2
Completed NCT00664157 - Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact of L-Dopa and Deep Brain Stimulation of Subthalamic Nucleus N/A
Completed NCT04524143 - The Acute Effect of Cervical Mobilization in Parkinson's Disease N/A
Completed NCT05107531 - Investigation of Gait, Foot Pressure Distribution and Balance in Parkinson's Patients With Motor Freezing
Completed NCT04524182 - The Acute Effect of Lumbosacral Mobilization in Parkinson's Disease N/A
Completed NCT00985517 - Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease Phase 1/Phase 2
Completed NCT01968031 - A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease Phase 3
Completed NCT01970813 - Efficacy of Acupuncture and Bee Venom Acupuncture on Patients With Idiopathic Parkinson's Disease N/A
Completed NCT01221948 - Vercise Implantable Stimulator for Treating Parkinson's Disease Phase 2
Terminated NCT01028586 - MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918) Phase 3
Completed NCT00239564 - Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease Phase 1/Phase 2
Completed NCT02240030 - Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes Phase 3
Completed NCT00605683 - MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist Phase 3
Completed NCT00400634 - Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease Phase 2
Completed NCT01227265 - Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037) Phase 3
Completed NCT01606670 - Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease
Completed NCT01617135 - Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes Phase 2
Terminated NCT00261781 - Walking Capacity in Parkinson's Disease (PD-Walk) N/A